Volume 10, Number 11—November 2004
Research
Evaluating Human Papillomavirus Vaccination Programs
Al V. Taira*, Christopher P. Neukermans†, and Gillian D. Sanders†‡
Table 2
Total discounted healthcare costs, total discounted life expectancy in years, and total quality-adjusted discounted lifetime expectancy in years are presented for prevaccination, and for female-only and male + female vaccination scenarios.
| Outcome | No vaccination | HPV-16/18 vaccination |
|
|---|---|---|---|
| Female-onlya | Female + maleb | ||
| Cost, $ | 40,423 | 40,667 | 40,929 |
| Incremental cost, $ | 244 | 261 | |
| Life expectancy, y | 28.7975 | 28.8112 | 28.8117 |
| Incremental life expectancy, d | 5.0 | 0.18 | |
| Quality-adjusted life expectancy, y | 27.7422 | 27.7590 | 27.7596 |
| Incremental quality-adjusted life expectancy, d | 6.1 | 0.21 | |
| Incremental cost-effectiveness | |||
| $ per life-year | 17,802 | 534,317 | |
| $ per quality-adjusted life-year | 14,583 | 442,039 | |
| % reduction in lifetime cervical cancer cases | 61.8 | 2.2 | |
aIncremental to no vaccination strategy.
bIncremental to a female-only vaccination strategy.
Page created: April 17, 2012
Page updated: April 17, 2012
Page reviewed: April 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.